Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus
2017-005026-37Phase 3Unknown
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2018
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Baricitinib 4 mg + standard-of-care with Placebo + standard-of-care (2 arms). Primary endpoint: SRI-4 response at primary time point. Status: unknown.
02
Drugs
baricitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2017-005026-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005026-37.